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Background
Hereditary spherocytosis (HS) is a chronic hemolytic anemia characterized by micro-
spherocytes in the peripheral blood and increased erythrocyte osmotic fragility (EOF). 
This study evaluated the cryohemolysis test (CHT); initial hemolysis (IH); immediate and 
incubated hemolysis percentage in 5.5 g/L NaCl (H5.5); mean corpuscular hemoglobin 
concentration (MCHC); red blood cell distribution width (RDW); and Hb/MCHC, 
Hb/RDW, and MCHC/RDW ratios for the diagnosis of HS.
Methods
Data from 13 patients with HS were evaluated at the Instituto de Bioquímica Aplicada 
and compared with data from 14 unaffected individuals and 11 patients with anemia due 
to another etiology. Total blood and reticulocyte counts, CHT, and immediate and in-
cubated EOF were performed in all subjects; sensitivity, specificity, efficiency, and Youden 
index (YI) were calculated.
Results
Eight patients with HS had MCHC ≥345 g/L, 10 had RDW ≥14.5%, 12 had IH ＞5.0 g/L, 
11 had immediate H5.5 ≥5%, and 13 had incubated H5.5 ≥50% (the cut-off value to 
consider HS). The efficiency and YI were: immediate H5.5 (0.94‒0.85), incubated H5.5 
(0.89‒0.82), IH (0.89‒0.78), MCHC (0.87‒0.62), CHT (0.84‒0.54), and Hb/MCHC (0.71‒
0.56), respectively. The calculated ratios could distinguish subjects with HS from un-
affected individuals (P＜0.05), but not those with anemia of another etiology (P＞0.05).
Conclusion
Although the CHT and supplementary hematimetric indexes were useful to differentiate 
individuals with SH from healthy controls, they cannot distinguish from anemias of other 
etiology. CHT and MCHC, in addition to EOF, are recommended for diagnosing HS pa-
tients because of their low cost and efficiency.
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INTRODUCTION
Hereditary spherocytosis (HS) is a heterogeneous disorder 
in which abnormalities of the red blood cell membrane struc-
tural proteins lead to the loss of membrane surface area, 
resulting in hyperdense, spherically-shaped erythrocytes 
with reduced deformability and reduced shorter half-life. 
The loss of surface area results from increased membrane 
fragility due to primary and secondary abnormalities in ery-
throcyte membrane proteins involved in the vertical joints 
between the cytoskeleton and the lipid bilayer, particularly 
ankyrin, α- and β-spectrin, band 3, and protein 4.2 [1, 2].
HS is inherited in an autosomal dominant manner in 
around two-thirds of patients, associated with mutations in 
the ankyrin, β-spectrin, or band 3 genes. In the remaining 
patients, inheritance is non-dominant due to autosomal re-
cessive inheritance or a de novo mutation [3].
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The osmotically fragile spherocytes are selectively trapped 
in the spleen and destroyed. Increased red blood cell destruc-
tion causes the main clinical features of typical HS: evidence 
of hemolysis with anemia, reticulocytosis, splenomegaly, 
jaundice, gallstone formation, spherocytes in a peripheral 
blood smear, and increased osmotic fragility of the 
erythrocytes. The degree of hemolysis varies from asympto-
matic patients who are incidentally diagnosed, to patients 
with severe disease, who are transfusion-dependent [4].
When investigating a patient suspected to have a mem-
brane-associated hemolytic anemia, a range of information 
is required, including family and clinical history, red cell 
indices and peripheral blood smear examination, reticulocyte 
count and negative direct Coombs test (DCT) findings, and 
the results of laboratory tests for hemolytic processes and 
membrane defects [5].
The principle for the traditional laboratory diagnostic tests 
of hereditary red cell membrane defects exploits the reduced 
surface area-to-volume ratio, as found in spherocytes. These 
tests measure the rate of red cell lysis in different incubation 
media. The erythrocyte osmotic fragility (EOF) test de-
termines the concentration of sodium chloride at which 50% 
of the fresh and incubated red cells are lysed. The glycerol 
lysis, acidified glycerol lysis time test (AGLT), and pink tests 
determine the extent or rate of the lysis of red cells suspended 
in buffered glycerol solutions. However, these tests do not 
differentiate HS from secondary spherocytosis associated 
with other conditions, mainly autoimmune hemolytic ane-
mias [6].
Streichman et al. [7] proposed in 1990 the cryohemolysis 
test (CHT) to identify HS, based on the observation that 
red blood cells of HS patients are particularly susceptible 
to cold (0oC) in hypertonic conditions. Later, King et al.  
[8] presented a rapid flow cytometric test for the diagnosis 
of HS in routine hematology. The flow cytometric test meas-
ures the fluorescence intensity of intact red cells labeled 
with eosin-5-maleimide (EMA) dye, which reacts covalently 
with Lys-430 on the first extracellular loop of band 3 protein. 
Finally, Won and Suh [9] developed the flow cytometry 
based OF (FCM OF) test to measure the residual red cell 
counts after the cells are exposed to hypotonic solutions.
British experts in 2011 recommended the implementation 
of cryohemolysis and EMA when the HS diagnosis was equiv-
ocal because of its high predictive value. However, in patients 
with family history, clinical and typical laboratory 
(spherocytes, increased mean corpuscular hemoglobin con-
centration [MCHC], and reticulocytosis) findings indicated 
that it was not necessary to perform additional diagnostic 
tests. Finally, gel electrophoresis analysis of erythrocyte 
membranes was the method of choice for the diagnosis of 
atypical cases [10].
The International Council for Standardization in Haema-
tology reported that all screening tests; i.e., the EOF test, 
AGLT test, osmotic gradient ektacytometry, and EMA bind-
ing test, can detect typical HS. In the absence of a family 
history, DCT and one screening test for HS should both 
be performed. If in doubt, they have advised the use of 
two of these screening tests [11].
Some authors have explored the discriminant capacity 
of hematimetric indices such as MCHC and red blood cell 
distribution width (RDW) [12], as well as ratios calculated 
from them (Hb/MCHC, Hb/RDW, and MCHC/RDW) [13]. 
These authors concluded that these indices were valuable 
complementary tools in the diagnosis and classification of 
disease severity.
The sensitivity and specificity of these tests vary according 
to different authors. The objective of this study was to de-
termine the efficiency in HS diagnosis of the CHT; EOF 
parameters (immediate and post-incubation hemolysis % in 
5.5 g/L NaCl and initial hemolysis); and the MCHC and 
RDW hematimetric indexes and their calculated ratios 
(Hb/MCHC, Hb/RDW, and MCHC/RDW).
MATERIALS AND METHODS
Design, sample, and techniques
A cross-sectional descriptive study was performed between 
November 2012 and March 2017 at the Instituto de 
Bioquímica Aplicada, Universidad Nacional de Tucumán 
(Argentina). The sample consisted of 38 individuals. Of these, 
14 were healthy controls, 13 had HS (4 adults and 9 children 
≤12 yr of age), and 11 had anemias due to other causes 
(4β-thalassemia trait carriers, 2 HbS heterozygous, 2 iron 
deficiency anemia [IDA], 2 non-spherocytic hemolytic ane-
mia, and 1 microcytic hypochromic anemia with normal 
iron level). The diagnosis of HS was based on signs and 
symptoms of hemolytic anemia plus osmotic fragility meas-
urements in fresh and incubated blood, as well as the presence 
of spherocytes in peripheral blood smears. Thalassemia pa-
tients were diagnosed on the basis of cell indices, cellulose 
acetate electrophoresis (CAE) at alkaline pH, and Hb A2 
level by microcolumn chromatography (BioSystem S.A., 
Barcelona, Spain). Sickle cell hemoglobinopathies were also 
diagnosed on the basis of CAE and sickling test results. IDA 
was diagnosed by determining serum iron concentration, 
total iron binding capacity (TIBC), and transferrin saturation 
(SAT) through colorimetric methods (Wiener Lab, Rosario, 
Argentina). Subjects with non-spherocytic hemolytic anemia 
(according to reticulocytes, bilirubin and lactate dehydrogen-
ase [LDH] levels) had negative direct Coombs test (DCT).
Blood samples were collected in K2-EDTA. The total blood 
count was measured by hematologic counter (Sysmex 
KX-21N, Kobe, Japan), reticulocytes were counted manually 
with brilliant cresyl blue dye, and DCT and cryohemolysis 
test (CHT) were also performed. Using the Hb measurement 
and hematimetric indexes, the Hb/MCHC, Hb/RDW, and 
MCHC/RDW ratios were calculated. MCHC ≥345 g/L and 
RDW ≥14.5% were considered indicative of HS.
Bilirubin and LDH levels were measured using an auto-
analyzer (Roche Cobas c311, Indianapolis, USA) in patients 
with a presumptive HS diagnosis. The reference values for 
LDH are 200-480 U/L, for total bilirubin (TBil) are up to 
1.2 mg/dL and indirect bilirubin (IBil) to 0.8 mg/dL.
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Table 1. Results in the normal, HS, and anemia due to other causes groups.
Parameters Normal (N=14) HS (N=13) Other anemia (N=11)
Age (yr) 28 (8–38) 7 (1–53) 10 (3–34)
MCV (fL) 89.5±3.5 81.6±6.6a) 73.3±13.0a)
MCH (pg) 29.4±1.1 28.6±3.0b) 22.6±5.8a)
MCHC (g/L)  329±5 350±16a,b)  305±26a)
RDW (%) 12.6±0.5 19.6±4.8a) 17.4±4.1a)
Reticulocytes (%)   0.9±0.3 10.2±4.9a,b)   2.8±3.8
Hb/MCHC 0.41±0.04 0.32±0.05a) 0.35±0.05a)
Hb/RDW 10.6±0.7   6.2±2.4a)   6.4±1.9a)
CHCM/RDW 26.2±1.0 19.0±5.1a) 18.4±4.4a)
CHT (%)   7.0±3.9 36.7±24.4a) 12.8±10.8
Immediate EOF (H50)   4.4±0.3   5.1±0.3a,b)   4.0±0.6a)
Incubated EOF (H50)   5.0±0.3   6.8±0.7a,b)   4.2±1.1a)
Initial hemolysis (g/L)   4.8±0.3   6.6±1.0a,b)   4.7±0.8
5.5 g/L NaCl immediate Hemolysis (%)   0.1±0.2 22.4±18.0a,b)   0.6±0.6a)
5.5 g/L NaCl incubated Hemolysis (%) 34.2±19.8 86.6±12.8a,b) 19.6±19.0
a)P＜0.05 between the normal and patient groups; b)P＜0.05 between the HS and other anemia groups.
Abbreviations: M, median; R, range; CHT, cryohemolysis test; EOF, erythrocyte osmotic fragility; H50, 50% hemolysis; MCH, mean 
corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; RDW, red blood cell 
distribution width.
The method described by Streichman et al. [7, 14, 15] 
was used to perform the CHT. The reagent occurs in a 0.7 
M buffered sucrose solution. The sample (500 μL) was placed 
into plastic tubes and washed 3 times with cold saline. A 
60% cell suspension in saline was prepared and kept in an 
ice bath until testing. Two milliliters of the buffered sucrose 
solution were incubated at 37oC for 10 minutes to equilibrate 
the temperature. Fifty μL of cell suspension was placed in 
the preheated sucrose solution, mixed manually for several 
seconds, and incubated at 37oC for exactly 10 minutes. 
Thereafter, the tubes were transferred to an ice bath, in-
cubated for exactly 10 minutes, and centrifuged at 1500 
rpm for another 10 minutes. The supernatant was read at 
540 nm (Metrolab 1600 plus, Rosario, Argentina). The test 
was performed twice in each subject and processed in parallel 
with a normal control. A hemolysate solution at 100% was 
prepared by pipetting 50 μL of the original sample in 2 
mL of distilled water. It was centrifuged and 200 μL of 
supernatant was placed in 4 mL of distilled water. The sol-
ution was mixed and read at 540 nm. To calculate the percent-
age of cryohemolysis, the optical density (OD) of the sample 
and 100% hemolysate was used according to the following 
formula:
Cryohemolysis [%]=(sample OD/hemolysate at 100% OD)×21
The normal range suggested in the literature is 3–15%, 
with CHT ＞20% suggestive of HS [7, 16]. Previously, in 
order to corroborate the normal range, our team studied 
30 healthy volunteers, finding a range of 4.0–12.5% [17]. 
As these results were similar to those in the literature, we 
adopted the recommended reference values.
Anticoagulated whole blood with lithium heparin was 
used for the EOF test, as described by Dacie and Lewis 
[16]. The samples were processed in parallel with a normal 
control. EOF was expressed as the concentration of NaCl 
required to produce 50% hemolysis (H50). The same proce-
dure was performed after the samples were kept at 37oC 
for 24 hours (incubated test). The reference values for imme-
diate and incubated EOF were 4.0–4.5 g/L and 4.6–5.9 g/L, 
respectively. It was considered indicative of HS, when 5.5 
g/L NaCl hemolysis tube showed a value ≥5% and ≥50% 
in the immediate and incubated test, respectively. Another 
index for HS was immediate initial hemolysis ≥5.0 g/L NaCl 
in the EOF test.
Ethical issues
This study was approved by Comité de Bioética de la 
Facultad de Medicina (Universidad Nacional de Tucumán), 
Tucumán, Argentina. Informed consent was obtained from 
all patients before inclusion in the study. In the case of 
children, the consent was provided by their parents.
Statistical analysis
IBM SPSS Statistics for Windows, version 20.0 was used 
to perform out all statistical analyses. All data except for 
age were presented as mean±standard deviation. Student’s-T 
tests were used for pairwise comparisons between groups. 
P＜0.05 was defined as the level of significance. The sensi-
tivity (Se) and specificity (Sp) of the tests for HS were calcu-
lated; receiver operating characteristic (ROC) curves were 
drawn and areas under the curve (AUC) were calculated. 
Efficiency and Youden index (YI) were calculated using the 
following formula:
Efficiency=true positives+true negatives/total number 
of cases
YI=Se+Sp–1
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Fig. 1. CHT and HS discriminator indices in the groups under study. 
Abbreviations: CHT, cryohemolysis test; HS, hereditary spherocytosis; MCHC, mean corpuscular hemoglobin concentration; N, normal; RDW, red 
blood cell distribution width.
RESULTS
Table 1 shows the results for the three groups under study: 
normal, HS and other anemia. The subjects with HS were 
children under 12 years of age in 9 cases; eight had a family 
history of hemolytic anemia, seven had been transfused at 
least once, and one had been splenectomized. Spherocytes 
were observed in all individuals with HS but also were seen 
in two patients with iron deficiency anemia and in one 
with β-thalassemia trait. Significant differences (P＜0.05) 
in almost all parameters were observed between healthy 
controls and HS individuals. The same was observed when 
comparing the normal group to those with other anemia, 
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Fig. 2. Receiver operating characteristic (ROC) curves of the test results for discriminating HS patients from those with other anemias A: ROC curves 
of CHT, MCHC, and RDW; B: ROC curves of calculated ratios. 
Abbreviations: CHT, cryohemolysis test; HS, hereditary spherocytosis; MCHC, mean corpuscular hemoglobin concentration; RDW, red blood cell 
distribution width.
Table 2. Sensitivity, specificity, efficiency, and Youden index of CHT, EOF parameters, and discriminative indices.
Tests Sensitivity Specificity Efficiency Youden index
MCHC 0.62 1.00 0.87 0.62
RDW 0.77 0.67 0.70 0.44
MCHC+RDW 1.00 0.68 0.79 0.68
CHT 0.62 0.92 0.84 0.54
Initial hemolysis 0.92 0.86 0.89 0.78
5.5 g/L NaCl inmediate hemolysis 0.85 1.00 0.94 0.85
5.5 g/L NaCl incubated hemolysis 1.00 0.82 0.89 0.82
Hb/MCHC 0.92 0.64 0.71 0.56
Hb/RDW 0.92 0.54 0.68 0.46
MCHC/RDW 0.77 0.58 0.65 0.35
Abbreviations: CHT, cryohemolysis test; HS, hereditary spherocytosis; MCHC, mean corpuscular hemoglobin concentration; RDW, red blood 
cell distribution width.
except for CHT, reticulocytes, initial hemolysis, and in-
cubated 5.5 g/L NaCl hemolysis % (P＞0.05).
CHT in the healthy control group showed a mean of 
7.0±3.9%; only one subject had a value of 18.9%, above 
the reference range (3–15%) but lower for considering HS 
(＞20%). Two children, one with heterozygous sickle cell 
anemia and one with β-thalassemia trait, showed CHT values 
of 35.7% and 32.0%, respectively (Fig. 1). For β-thalassemia 
carriers, the CHT levels were 15.3±11.6%. According to the 
ROC curve analysis, the optimum cutoff value to separate 
normal subjects from patients with HS was 15%. In these 
conditions, the computed test sensitivity and specificity were 
83% and 88%, respectively (Fig. 2).
Comparison between the HS and other anemia groups 
revealed significant differences (P＜0.05) in mean corpus-
cular Hb (MCH), MCHC, reticulocytes, CHT, immediate and 
incubated H50, initial hemolysis, and immediate and in-
cubated 5.5 g/L NaCl hemolysis % (Table 1).
The HS group had LDH, total bilirubin (TBil) and indirect 
bilirubin (IBil) levels above the reference values 
(LDH=606±173 U/L; TBil=2.63±1.10 mg/dL; IBil=2.02±1.08 
mg/dL). Eight HS patients had MCHC ≥345 g/L, and 10 
had RDW ≥14.5%. One child with heterozygous sickle cell 
anemia exhibited a very high RDW (Fig. 1). Twelve HS 
subjects presented with an initial hemolysis ≥5.0 g/L; 11 
showed immediate hemolysis at NaCl 5.5 g/L ≥5%; and 
the incubated hemolysis at NaCl 5.5 g/L was ≥50% in the 
HS group. Reticulocyte counts also revealed the presence 
of Heinz bodies in three individuals with HS and in one 
with sickle cell hemoglobinopathy.
The ROC curves for MCHC and RDW, with AUC of 0.91 
and 0.84, respectively, demonstrated that the best cutoff 
values were used in the actual study (Fig. 2). The combination 
of MCHC and RDW as a screening tool increased the Youden 
index values (Table 2).
The Hb/MCHC, Hb/RDW, and MCHC/RDW ratios dis-
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criminated HS patients from healthy controls (Fig. 1). 
However, they could not differentiate HS subjects from those 
with anemia due to other causes and no significant differences 
(P＞0.05) were observed between them. The Hb/MCHC ratio 
was much higher in two HS male patients because they 
had greater Hb values (134 and 154 g/L, respectively). In 
contrast, two children with very low Hb, one with HS and 
the other with S hemoglobinopathy, had lower Hb/MCHC 
ratios (Fig. 1). Regarding Hb/RDW ratio, two male subjects 
(HS and normal) showed higher values due to higher Hb 
levels (154 and 161 g/L, respectively) (Fig. 1). Among healthy 
controls, the ranges and cutoff value for HS ratios, according 
ROC curves, were Hb/MCHC=0.37–0.46 and ＜0.37; Hb/RDW= 
9.7–12.0 and ＜9.7; MCHC/RDW=24.3–27.9 and ＜24.3, re-
spectively (Fig. 2).
According to the sensitivity, specificity, efficiency, and 
Youden index analyses, the best test to discriminate HS was 
hemolysis percentage in 5.5 g/L NaCl in the immediate and 
incubated EOF tests (Table 2). According to the efficiency 
analysis, the best tests were initial hemolysis in EOF test, 
MCHC, CHT, and Hb/MCHC ratio, in that order. The Youden 
index for RDW, Hb/RDW, and MCHC/RDW reached the 
lowest values.
DISCUSSION
The correct diagnosis of HS and its differentiation from 
other causes of increased hemolysis is of critical importance 
for therapeutic decisions. Although British experts recom-
mend no further testing when family history and laboratory 
findings match the diagnosis of HS, specific tests are still 
necessary in order to assess the fragility of red blood cells 
to confirm the diagnosis in geographical areas where the 
prevalence of the disease is low. However, there are also 
cases of very mild expression and other atypical cases in 
which several tests are required to confirm the diagnosis. 
It is, therefore, very important to consider the specificity, 
sensitivity, and efficiency of the methods used in the de-
tection of HS.
The survey by the European Network for Rare Red Cell 
Anemias showed that the most frequently used tests for 
HS diagnosis included EMA binding (60% of centers) and 
immediate EOF and acidified glycerol lysis time test (around 
50% of centers). Less than 20% of the centers used the 
CHT. Ektacytometry, sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE), and molecular analysis were 
performed only in selected atypical cases [18]. Therefore, 
despite the recommendations of the British Committee for 
Standards in Haematology, the CHT has not yet been in-
corporated by many HS diagnostic centers [10]. The survey 
also revealed a lack of consensus on which screening test(s) 
have the best specificity and sensitivity for detecting HS. 
The majority of centers indicated the use of a combination 
of tests [18].
The CHT values for the normal group in the present study 
were similar to those reported by Streichman and Gescheidt 
in 42 healthy controls (7.0±4.4%); however, the HS groups 
were more heterogeneous (36.7±24.4%) because for them 
CHT values were 42±13% [15]. In 1990, Streichman et al. 
reported a CHT sensitivity of 100% and specificities of 94%, 
97%, and 86% in healthy controls, hospitalized patients, 
and autoimmune hemolytic anemia (AIHA) patients, re-
spectively [7]. Similarly, Iglauer et al. [19] calculated a 95% 
sensitivity and 96% specificity; however, the CHT sensitivity 
reported by Mariani et al. [20] was just 53%. Crisp et al. 
[21] reported a 78.7% sensitivity and 95.3% specificity and 
found the CHT more efficient than the EMA binding test. 
However, Park et al. [22] reported CHT sensitivity and specif-
icity of 48.5% and 76.7%, respectively; when CHT was com-
pared to the EMA binding and FCM OF tests, it showed 
the worst behavior. In agreement with the majority of the 
authors, in the present study, CHT was very specific (92%) 
but moderately sensitive (62%). The differences may be due 
to the different types of anemia included in the group of 
patients with another etiology, which was mainly microcytic 
hypochromic. Iglauer et al. [19] included mostly patients 
with hemolytic anemia, while Park et al. [22] selected sub-
jects with anemia of chronic disease (ACD), iron deficiency 
anemia (IDA), and AIHA. In addition, there were methodo-
logical differences, as well as differences in reference ranges, 
among the studies. According to the ROC curve analysis, 
the method sensitivity would be improved by changing the 
cutoff to 15%.
The spherocytic shape and surface area/volume ratio of 
red cells do not influence the CHT. The HbS erythrocytes 
in one patient were sensitive in the CHT. This effect was 
described by Streichman et al., who found it to be in-
dependent of the patient's clinical condition and the hemato-
logic parameters. On the other hand, β-thalassemia trait 
carriers were no more resistant to cryohemolysis than pa-
tients with normal cells, as reported by Streichman et al. 
[14]. Conversely, one patient showed increased CHT values. 
Recently, Crisp et al. [23] demonstrated that patients with 
HS have a lower level of aquaporin-1 (AQP1) in their eryth-
rocyte membranes, which is correlated with the disease 
severity. The behavior of erythrocytes in the CHT does not 
depend only on membrane protein defects but also on the 
depletion of AQP1. Therefore, multiple mechanisms may 
explain blood cell lysis in cold hypertonic media.
The Youden index is a main summary statistic of ROC 
curves used for the interpretation and evaluation of a bio-
marker and defines their maximum potential effectiveness. 
The immediate and incubated hemolysis percentage in 5.5 
g/L NaCl and initial hemolysis in the EOF test showed the 
highest Youden index levels. This particular salt concen-
tration was chosen because it provided the best discrim-
inatory results between normal and HS samples in previous 
studies. Streichman and Gescheidt observed that the in-
cubated EOF at 5.5 g/L NaCl was a much better parameter 
than the salt concentration that causes 50% hemolysis (H50) 
because it identified all probands, but failed to identify two 
obligatory carriers of the disease, while the H50 resulted 
in six false negative subjects [15]. Similar to previous reports, 
Blood Res 2018;53:10-7. bloodresearch.or.kr
16 Ledesma Achem Miryam Emilse, et al. 
the sensitivity of the EOF was greater when performed on 
incubated blood than on fresh blood [15, 20, 24]. With respect 
to initial hemolysis, Aixalá and Sarandria described similar 
results (6.1±1.1) [25]. The efficiency of the immediate and 
incubated 5.5 g/L NaCl in a single tube makes this an advisable 
screening method for laboratories that lack the specific metho-
dology for HS diagnosis. 
The hematimetric indices provided by hematological 
counters are inexpensive and not time-consuming and pro-
vide an automatic red cell morphological description. Red 
blood cells in patients with HS have a normal shaped when 
young but become progressively thicker with age. The mean 
cell volume (MCV) decreases slightly and the MCHC in-
creases as they acquire the spherocytic and hyperchromic 
appearances typical of the disorder [26]. The reticulocyte 
response of these individuals, together with the presence 
of microspherocytes, results in marked anisocytosis in pe-
ripheral blood smears and an increased RDW [12]. 
Automated MCHC and RDW measurement is useful for the 
diagnosis of HS. Michaels et al. [27] reported that an MCHC 
cutoff value ＞350 g/L provided 70% sensitivity and 86% 
specificity; similarly, they were 85% and 97%, respectively, 
with an RDW cutoff ＞14%. Eberle et al. [12] proposed 
different cutoff levels (MCHC＞345 g/L and RDW＞14.5%); 
for MCHC, they reported a 86.17% sensitivity and 90.43% 
specificity and 93.62% and 88.30%, respectively, for RDW. 
Using an MCHC＞355 g/L as diagnostic criteria for HS, Tao 
et al. [28] observed a sensitivity of only 41.07% and specificity 
of 94.47%. However, only MCHC appeared to be a good 
marker of disease because RDW was not sensitive and specific 
and had one of the lowest Youden index values (0.44). 
Although the MCHC and RDW are sufficiently efficient, 
not all patients with HS demonstrated elevation of both 
indexes. Like Michaels et al., the combination of both indexes 
increased sensitivity to 100% and Youden index at 0.68 [27].
Patients with HS had significantly lower Hb/MCHC, 
Hb/RDW, and MCHC/RDW ratios than those of the healthy 
controls in the present study; however, these indexes did 
not differ significantly from those of patients with other 
anemia. These results can be attributed to the decreased 
Hb and increased MCHC and RDW in patients with HS. 
For Rocha et al., [13] these ratios appeared to be more sensi-
tive markers than MCHC and RDW alone. However, the 
actual results did not match; thus, the calculated indexes 
were very sensitive but not specific. The Hb/MCHC range 
in healthy controls was similar to the 0.36–0.48 reported 
by Park et al.; however, they described a higher ratio in 
HS subjects than in patients with AIHA, ACD, and IDA. 
The last effect was not observed in the present study, likely 
because Park et al. [22] observed higher MCHC values in 
subjects with other anemias. 
The most traditional method for HS diagnosis is the EOF 
test; however, it is laborious and cumbersome. Several au-
thors reported that EOF failed to identify nearly one-quarter 
of patients with HS [4, 15, 19, 21, 29], but incubated EOF 
is still generally considered the gold standard for diagnosing 
HS in patients with DCT-negative hemolytic anemia [24]. 
EMA binding and FCM OF tests are satisfactory for discrim-
inating patients with HS since their sensitivity and specificity 
were, respectively, above 70% and 95% [21, 22, 30-32]. Since 
flow cytometers are not available in all diagnostic labo-
ratories, as well as specific tests for HS diagnosis, the immedi-
ate and incubated EOF at 5.5 g/L NaCl single tube may 
be an alternative screening method.
A limitation of this work is the lack of measurement of 
EMA binding, which is recommended in cases of equivocal 
HS diagnosis [10, 11, 32]. Therefore, it is likely that mild 
cases of HS were not detected using the actual diagnostic 
tests. The low number of samples is another limitation of 
this report and is related to the low prevalence of the pathol-
ogy in the study region.
It is clear that the definitive diagnosis of HS, especially 
mild and atypical cases, requires several laboratory tests. 
Bolton-Maggs et al. [29] recommended the selection of an 
appropriate test for determining mild or atypical HS con-
dition in a patient should consider the sensitivity and specific-
ity of the test for HS, the complexity of the protocol, and 
the total cost of instrument(s) and its maintenance. In low-in-
come countries, besides EOF test, the CHT and MCHC are 
advisable for the diagnosis of HS patients because of their 
low cost, simple procedure, quick results, minimal blood 
sample requirement, and specificity. 
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